MIRA Pharmaceuticals Reports Promising Ketamir-2 Results for PTSD

MIRA Pharmaceuticals announced positive outcomes from research on its drug candidate, Ketamir-2, which restored normal behavior in animals stressed to mimic PTSD symptoms. Currently in a Phase 1 trial for neuropathic pain, Ketamir-2 shows potential for broader application in neuropsychiatric disorders, particularly PTSD.

The company conducted the study using the Single Prolonged Stress (SPS) model with rats exposed to stressors. Post-stress behavioral improvements were noted after oral administration of Ketamir-2, indicating a reversal of PTSD-like behaviors.

CEO Erez Aminov emphasizes the drug's potential for PTSD, highlighting future collaborations with military and government bodies to address significant treatment gaps. The study supports further exploration of Ketamir-2 in treating neuropsychiatric disorders.